Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision reversing a district court’s ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

The Federal Circuit reversed a Delaware district court’s 2023 ruling axing a Novartis Pharmaceuticals Corp. patent covering ...

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

Marea’s Phase IIa study enrolled patients with hypertriglyceridemia—too much fat in the blood. The latest results showed the ...

Novartis’ Zolgensma, an IV formulation, was FDA-approved in 2019 for patients under two with SMA. However, the new IT ...

Range Financial Group LLC acquired a new stake in shares of Novartis AG (NYSE:NVS – Free Report) in the fourth quarter, ...

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully ...

Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025Additional clinical ...

First Hawaiian Bank lessened its position in Novartis AG (NYSE:NVS – Free Report) by 2.8% during the 4th quarter, according ...